Pherin Pharmaceuticals: VistaGen licenses nasal spray for the treatment of social anxiety disorder

VistaGen Therapeutics has acquired exclusive global rights to PH94B aloradine nasal spray, which Pherin Pharmaceuticals has been developing for the treatment of social anxiety disorder (SAD), the company said. A Phase 3 study of PH94B for SAD is planned for the first half of 2019. Pherin received $2.25 million of unregistered common stock from VistaGen [...]